The emerging role of γδ T cells in cancer immunotherapy. (July 2019)

• Record Type: Journal Article
• Authors: Nussbaumer, Oliver; Koslowski, Michael
• Is Part Of: Immuno-oncology technology. Volume 1(2019)
• Page Start: 3
• Page End: 10
• Publication Date: 2019-07
• Subjects: γδ T cells -- Adoptive cell therapy -- Immunotherapy -- Cancer; Cancer -- Immunotherapy -- Periodicals; 616.994061
• DOI: 10.1016/j.iotech.2019.06.002
• Languages: English
• ISSNs: 2590-0188

Abstract

Abstract: The recent successes of chimeric antigen receptor T cells in the treatment of hematological malignancies have clearly led to an explosion in the field of adoptive cell therapy for cancer. Current efforts are focused on the translation of this exciting technology to the treatment of solid tumors and the development of allogeneic 'off-the-shelf' therapies. γδ T cells are currently gaining considerable attention in this field as their unique biology and established role in cancer immunosurveillance place them in a unique position to potentially overcome these challenges in adoptive cell therapy. Here, we review the relevant aspects of the function of γδ T cells in cancer immunity, and summarize clinical observations and clinical trial results that highlight their emerging role as a platform for the development of safe and effective cancer immunotherapies. Abstract : γδ T cells provide tissue- and blood-resident cancer surveillance, combining adaptive T cell biology with the innate recognition of malignant events in a non-clonally selected and MHC-unrestricted fashion. This unique combination renders γδ T cells an attractive target for clinical development of fully allogeneic adoptive cell therapies, genetic manipulation and targeted immunotherapies. Highlights: γδ T cells are a unique subset of T cells combining innate and adaptive features. Tissue-resident γδ T cells have important functions in tissue and cancer immunosurveillance. γδ T cells are being exploited increasingly for cancer immunotherapy.